Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Change in Account Payables: 2011-2025

Historic Change in Account Payables for Adma Biologics (ADMA) over the last 11 years, with Sep 2025 value amounting to -$4.9 million.

  • Adma Biologics' Change in Account Payables fell 401.36% to -$4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year increase of 62.92%. This contributed to the annual value of $4.2 million for FY2024, which is 8.10% up from last year.
  • Per Adma Biologics' latest filing, its Change in Account Payables stood at -$4.9 million for Q3 2025, which was down 152.62% from $9.3 million recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Change in Account Payables peaked at $13.8 million during Q3 2022, and registered a low of -$12.0 million during Q4 2022.
  • For the 3-year period, Adma Biologics' Change in Account Payables averaged around $1.1 million, with its median value being $142,000 (2025).
  • Per our database at Business Quant, Adma Biologics' Change in Account Payables soared by 16,280.00% in 2024 and then tumbled by 401.36% in 2025.
  • Over the past 5 years, Adma Biologics' Change in Account Payables (Quarterly) stood at -$4.9 million in 2021, then plummeted by 146.61% to -$12.0 million in 2022, then surged by 141.73% to $5.0 million in 2023, then decreased by 21.07% to $3.9 million in 2024, then slumped by 401.36% to -$4.9 million in 2025.
  • Its Change in Account Payables was -$4.9 million in Q3 2025, compared to $9.3 million in Q2 2025 and $142,000 in Q1 2025.